Skip to Content

Rezonic FDA Approval Status

FDA Approved: No
Brand name: Rezonic
Generic name: casopitant
Company: GlaxoSmithKline
Treatment for: Nausea/Vomiting, Chemotherapy Induced, Nausea/Vomiting, Postoperative

Rezonic (casopitant) is an investigational NK-1 receptor antagonist in development as add-on therapy for the prevention of chemotherapy-induced nausea and vomiting, and also for the prevention of postoperative nausea and vomiting.

Development Timeline for Rezonic

DateArticle
Sep 28, 2009GSK Provides Update on Regulatory Filings for Zunrisa/Rezonic
May 29, 2008GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic/Zunrisa (Casopitant)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.